Investor Overview

Stock Information
Loading data...

Shares outstanding

1,992,032 (as of 5/17/2023)

Press Releases
Jun 1, 2023

Increased net product revenue more than 35% in the first quarter of 2023 vs. prior year quarter Reduced operating expenses more than 70% Decreased loss from operations more than 85% Reaffirms path...

May 17, 2023

-- CUSIP number for Evofem will change to 30048L302 on May 18, 2023 -- -- Ticker symbol will change to "EVFMD" for 20 business days, then revert to "EVFM" -- SAN DIEGO, May 17, 2023 /PRNewswire/...

Apr 28, 2023

-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs. 2021, exceeding stated goal -- -- Evofem targeting EBITDA...

Apr 14, 2023

Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO)...

Apr 12, 2023

— Improves Phexxi coverage for more than 5.8 million New York lives — — Year-to-date, Evofem has gained Phexxi coverage for more than 22.1 million new lives — SAN DIEGO, April 12, 2023...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The U.S. contraceptive market was estimated at $7.9 billion as of 2021. Every 1% market share of the 42.2 million women in our addressable market represents more than $300 million in net product sales for Evofem.

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

Effective October 3, 2022, the Company's common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM". For 20 business days following May 18, 2023, it will trade under the ticker symbol "EVFMD," after which time it will revert to the ticker symbol "EVFM".

Featured Event
Tuesday, June 20, 2023
08:00 am - 09:00 am PDT

The record date for the 2023 Annual Meeting of Stockholders is April 24, 2023.

View All

Latest Financial Results

Q2 2022, Ended June 30th, 2022

Earnings Release
Earnings Call
10-Q Filing